Document is current
Any future updates will be listed below
-
Authors
Matsuhisa, Munehide https://orcid.org/0000-0003-4624-939X
Miyoshi, Hideaki https://orcid.org/0000-0002-5909-3243
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
Takahashi, Yoko https://orcid.org/0000-0003-2481-9574
Morimoto, Yukiko
Terauchi, Yasuo https://orcid.org/0000-0002-8872-3697
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000044126 at UMIN JapanDocuments that mention this clinical trial
Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study
https://doi.org/10.1007/s13300-022-01333-w
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
https://doi.org/10.1007/s13300-024-01531-8
Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study
https://doi.org/10.1007/s13300-023-01373-w
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 26 October 2022
First Online: 23 November 2022
